Costs of diabetes care and treatment satisfaction in type 2 diabetes patients treated with a basal-bolus (ICT) insulin regimen in outpatient care: Results of the LIVE-COM study;Diabetesbezogene Kosten und Therapiezufriedenheit bei ICT-behandelten Typ-2-Diabetikern in der ambulanten Versorgung: Ergebnisse der LIVE-COM-Studie

Medizinische Klinik

Volumn 105, Issue 11, 2010, Pages 792-801

  Bierwirth, Ralph Achim ^a   Kohlmann, Thomas ^b   Moock, Jörn ^b   Holle, Rolf ^c   Landgraf, Wolfgang ^d,e  

^a ELISABETH KRANKENHAUS ESSEN   (Germany)

^b UNIVERSITY OF GREIFSWALD   (Germany)

^c INSTITUTE OF EPIDEMIOLOGY   (Germany)

^d DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^e SANOFI AVENTIS DEUTSCHLAND GMBH   (Germany)

Author keywords

Basal bolus therapy; Cost minimisation analysis; Insulin detemir; Insulin glargine; Treatment costs; Type 2 diabetes

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C; INSULIN; INSULIN DETEMIR; INSULIN GLARGINE;

ARTICLE; BOLUS INJECTION; CONTROLLED STUDY; COST MINIMIZATION ANALYSIS; COST OF ILLNESS; COST UTILITY ANALYSIS; DOSE RESPONSE; DRUG COST; DRUG DOSE COMPARISON; GLUCOSE BLOOD LEVEL; HEALTH INSURANCE; HEMOGLOBIN BLOOD LEVEL; HUMAN; INSULIN INFUSION; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; OUTPATIENT CARE; PATIENT SATISFACTION; TREATMENT DURATION;

AGED; AMBULATORY CARE; COST-BENEFIT ANALYSIS; CROSS-SECTIONAL STUDIES; DIABETES MELLITUS, TYPE 2; FEMALE; GERMANY; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN, LONG-ACTING; MALE; MIDDLE AGED; NATIONAL HEALTH PROGRAMS; PATIENT SATISFACTION; PRIMARY HEALTH CARE;

EID: 78651394242     PISSN: 07235003     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00063-010-1136-1     Document Type: Article

References (27)

1. H. Hauner I. Köster I. Schubert 2007 Trends in der Prävalenz und ambulanten Versorgung von Menschen mit Diabetes mellitus Dtsch Arztebl 104 41 A2799 2805
2. I. Köster L. v. Ferber P. Ihle, et al. 2006 The cost burden of diabetes mellitus: the evidence from Germany - the CoDiM study Diabetologia 49 7 1498 1504 10.1007/s00125-006-0277-5 16752168
3. S. Matthaei R. Bierwirth A. Fritsche, et al. 2009 Medikamentöse antihyperglykämische Therapie des Diabetes mellitus Typ 2 Diabetologie 4 32 64 10.1055/s-0028-1098798
4. P. Mullins P. Sharplin H. Yki-Järvinen, et al. 2007 Negative binomial metaregression analysis of combined glycosylated hemoglobin and hypoglycemia outcomes across eleven phase III and IV studies of insulin glargine compared with neutral protamine Hagedorn insulin in type 1 and type 2 diabetes mellitus Clin Ther 29 1607 1619 1:CAS:528:DC%2BD2sXhtFyjt7jP 10.1016/j.clinthera.2007.08.020 17919543
5. M.A. Baxter 2008 The role of new insulin analogues in the initiation and optimisation of insulin therapy in type 2 diabetes Acta Diabetol 45 253 268 1:CAS:528:DC%2BD1cXhtlSktL3J 10.1007/s00592-008-0052-9 18766296
6. D.R. Owens G.B. Bolli 2008 Beyond the era of NPH insulin - long-acting insulin analogs: chemistry, comparative pharmacology, and clinical application Diab Technol Ther 10 5 333 349 1:CAS:528:DC%2BD1cXhtVWksL3P 10.1089/dia.2008. 0023
7. F. Porcellati P. Rossetti N.R. Busciantella, et al. 2007 Comparison of pharmacokinetics and dynamics of the long-acting insulin analogs glargine and detemir at steady state in type 1 diabetes Diabetes Care 30 2447 2452 1:CAS:528:DC%2BD2sXht1CltrvL 10.2337/dc07-0002 17623819
8. J. Rosenstock M. Davies P.D. Home, et al. 2008 A randomised, 52-week, treat-to-target trial comparing insulin detemir with insulin glargine when administered as add-on to glucose-lowering drugs in insulinnaive people with type 2 diabetes Diabetologia 51 408 416 1:CAS:528:DC%2BD1cXhtlyls7c%3D 10.1007/s00125-007-0911-x 18204830
9. S. Swinnen J.H. DeVries 2009 Higher dose requirements with insulin detemir in type 2 diabetes - three cases and a review of the literature Diab Res Clin Prac 84 e24 e26 1:CAS:528:DC%2BD1MXktlyqs7w%3D 10.1016/j.diabres.2009.02. 009
10. H. Hauner T. Kohlmann W. Landgraf, et al. 2009 Kosten für antihyperglykämische Arznei- und Verbrauchsmittel und Therapiezufriedenheit bei Typ-2-Diabetes Dtsch Med Wochenschr 134 1207 1213 1:STN:280: DC%2BD1Mzns1GlsA%3D%3D 10.1055/s-0029-1222595 19472091
11. E.-G. Hagenmeyer A. Höer M. Kulik, et al. 2009 Versorgungsforschung zur Behandlung von Typ-2-Diabetikern mit Insulin. Ressourcenverbrauch und Kosten unter Therapie mit Insulin glargin oder NPH-Insulin (LIVE-KK) MMW-Fortschr Med Originalien II 63 70
12. O. Schöffski L. Breitscheidel U. Benter, et al. 2008 Resource utilisation and costs in patients with type 2 diabetes mellitus treated with insulin glargine or conventional basal insulin under real-world conditions in Germany: LIVE-SPP study J Med Economics 11 695 712 10.3111/13696990802645726
13. F.-W. Dippel T. Schneider C. Rosak, et al. 2009 Behandlungskosten bei insulinpflichtigen Diabetikern unter Insulin glargin versus Insulindetemir - Ergebnisse einer repräsentativen Verordnungsdatenanalyse Perfusion 22 194 199
14. F.-W. Dippel T. Schneider O. Schöffski, et al. 2009 Insulin glargin: eine kostengünstige Alternative im Vergleich zu NPH-Insulin Monitor Versorgungsforschung 6 31 35
15. E.G. Hagenmeyer H. Gothe W. Landgraf, et al. 2010 Ressourcen- Inanspruchnahme und Kosten der Behandlung von Typ-2-Diabetikern unter Insulin glarginoder Insulindetemir-Therapie (LIVE-KK) Gesundheitsökonomie u Qualitätsmanagement 15 121 126 10.1055/s-0028-1110023
16. S. Pscherer E.S. Dietrich F.-W. Dippel, et al. 2010 Comparison of one-year costs of type 2 diabetes treatment with insulin glargine or insulin detemir in a basal supported oral therapy (BOT) in Germany Int J Clin Pharm Therap 2 129 137
17. S. Pscherer E.S. Dietrich F.-W. Dippel, et al. 2010 Cost comparison of insulin glargine with insulin detemir in a basal-bolus regime with mealtime insulin aspart in type 2 diabetes in Germany GMS Ger Med Sci 8 Doc17
18. J.M. von der Graf Schulenburg W. Greiner F. Jost, et al. 2007 Deutsche Empfehlungen zur gesundheitsökonomischen Evaluation - dritte und aktualisierte Fassung des Hannoveraner Konsens Gesundh ökon Qual manag 12 285 290 10.1055/s-2007-963505
19. Deutsche Gesellschaft für Epidemiologie (DGepi). Leitlinien und Empfehlungen zur Sicherung von Guter Epidemiologischer Praxis (GEP). http://www.dgepi.de/pdf/infoboard/Leitlinien/GEP.pdf (letzter Zugriff am 9.11.2010).
20. H. Schön K.H. Theobald P.K. Schädlich 2009 How to gain high data quality in a non-interventional trial taking the LIVE-COM Study as example Value in Health 12 Suppl A392
21. P. Hollander J. Cooper J. Bregnhoj, et al. 2008 A 52-week, multinational, open-label, parallel-group, noninferiority, treat-to-target trial comparing insulin detemir with insulin glargine in a basal-bolus regimen with mealtime insulin aspart in patients with type 2 diabetes Clin Ther 30 11 1976 1987 1:CAS:528:DC%2BD1MXhsV2gurg%3D 10.1016/j.clinthera.2008.11.001 19108786
22. S. Heller C. Koenen Bode B 2009 Comparison of Insulin detemir and insulin glargine in a basal-bolus regimen, with insulin aspart as the mealtime insulin, in patients with type 1 diabetes: a 52-week, multinational, randomized, open-label, parallel-group, treat-to-target noninferiority trial Clin Ther 31 10 2086 2097 1:CAS:528:DC%2BD1MXhsFGlsrbI 10.1016/j.clinthera.2009.10.006 19922879
23. Diashop Diabetikerversand. http://www.diashop.de (letzter Zugriff am 28.10.2008).
24. J. Moock F. Hessel D. Ziegeler, et al. 2010 Development and testing of the Insulin Treatment Experience Questionnaire (ITEQ) The Patient 3 1 45 58
25. IMS, Institut für Medizinische Statistik. Frankfurt, Oktober 2008.
26. R. Bierwirth K. Kostev F.-W. Dippel, et al. 2010 Ressourcenverbrauch und Behandlungskosten unter einer intensivierten konventionellen Therapie (ICT) mit Insulin glargin, Insulindetemir oder NPH-Insulin bei Patienten mit Typ-1-Diabetes Perfusion 3 96 103
27. T. Wiesner P.K. Schädlich F.-W. Dippel, et al. 2010 Insulin glargin versus Insulindetemir in der Basal-Bolus-Behandlung von Patienten mit Typ-1-Diabetes mellitus Perfusion 23 56 65